Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous ...

1HyQvia® (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion), Product Monograph, Takeda Canada Inc. (March 13, 2025).

Intravitreal injection of plasmin and hyaluronidase induced complete posterior vitreous detachment with no obvious toxicity in an animal study. Zhi-Liang Wang, MD, and colleagues performed ...

If you want to dissolve your dermal filler without going to the doctor and getting an injection of hyaluronidase, your only option is to wait it out. Hyaluronic acid filler can last anywhere from ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has expanded the marketing authorization (NOC) for HyQvia® (normal immunoglobulin [human] 10% and recombinant human ...

The Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj in combination with carfilzomib, a proteasome inhibitor, and dexamethasone for the treatment of adults with ...

1 HyQvia® (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion), Product Monograph, Takeda Canada Inc. (March 13, 2025).